April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Confirmation Of "Likely Progression" In Standard Automated Perimetry Using Guided Progression Analysis
Author Affiliations & Notes
  • Jonathan Y. Wong
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Mauro T. Leite
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Roman G. Fajardo
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Ali Tafreshi
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Linda M. Zangwill
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Robert N. Weinreb
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Christopher A. Girkin
    Ophthalmology, Univ of Alabama at Birmingham, Birmingham, Alabama
  • Jeffrey M. Liebmann
    Ophthalmology, NYU School of Medicine, New York, New York
  • Pamela A. Sample
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Felipe A. Medeiros
    Ophthalmology, Hamilton Glaucoma Center -UCSD, San Diego, California
  • Footnotes
    Commercial Relationships  Jonathan Y. Wong, None; Mauro T. Leite, None; Roman G. Fajardo, None; Ali Tafreshi, None; Linda M. Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering (R), Heidelberg Engineering GmbH (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Robert N. Weinreb, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (F, C), Heidelberg Engineering GmbH (F), Merck Inc. (C), Novartis (F), Optovue Inc. (F, C), Pfizer Inc. (C), Topcon Medical Systems Inc. (F); Christopher A. Girkin, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering Inc. (R), Merck Inc. (R), Optive Inc. (R), Pfizer Inc. (C), Topcon Medical Systems Inc. (R); Jeffrey M. Liebmann, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (F), Dyopsis Corp. (F, C), Heidelberg Engineering Inc. (F), Optovue Inc. (F, C), Pfizer Inc. (C), Topcon Medical Systems Inc. (F, C); Pamela A. Sample, Carl Zeiss Meditec Inc. (F), Haag-Streit (F); Felipe A. Medeiros, Alcon Laboratories Inc. (F, C, R), Allergan Inc. (C, R), Carl Zeiss Meditec Inc. (F, R), Merck Inc. (F), Pfizer Inc. (F, C, R), Reichert Inc. (R)
  • Footnotes
    Support  NEI grants U10EY14267,RO1EY19869, and RO1EY08208,RO1EY11008,RO1EY13959;Eyesight Foundation of Alabama;Alcon;Allergan;Pfizer;Merck;Santen;Corrine Graber Research Fund NY Glaucoma Research Inst.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan Y. Wong, Mauro T. Leite, Roman G. Fajardo, Ali Tafreshi, Linda M. Zangwill, Robert N. Weinreb, Christopher A. Girkin, Jeffrey M. Liebmann, Pamela A. Sample, Felipe A. Medeiros; Confirmation Of "Likely Progression" In Standard Automated Perimetry Using Guided Progression Analysis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the ability of standard automated perimetry (SAP) guided progression analysis (GPA) to confirm "likely progression" in subsequent tests.

Methods: : 85 eyes from 69 glaucoma patients were included in this observational cohort study. Patients were recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) and from the African Descent and Glaucoma Study (ADAGES). To be included, patients were required to have a minimum of 3 years of follow-up and at least 8 reliable SAP tests. All eyes had "likely progression" as defined by the GPA, which was based on the presence of 3 or more points with significant change compared to the baseline visual fields and repeatable in 3 tests. We then evaluated all available visual fields after the initial diagnosis of "likely progression" by the GPA, in order to assess the proportion of fields in which this diagnosis was subsequently confirmed or not. Univariable Cox models were built to evaluate the predictive ability of age, baseline mean deviation, baseline pattern standard deviation (PSD), central corneal thickness and baseline intraocular pressure in predicting those eyes that had confirmation of "likely progression" in all subsequent fields.

Results: : The average follow-up time was 10 years and the average number of subsequent visual fields performed after the initial diagnosis of "likely progression" was 6 (range 3-11). 36 of 85 eyes (42.9%) confirmed "likely progression" on all subsequent SAP tests while 41 of 85 eyes (48.2%) confirmed "likely progression" on at least 75% of subsequent SAP tests and 54 of 85 eyes (63.5%) confirmed "likely progression" on at least 50% of subsequent SAP tests. 10 of 85 eyes (11.8%) had no confirmation of "likely progression" in any of the subsequent visual fields. The only baseline characteristic that was predictive of confirmed "likely progression" in all subsequent visual fields was the SAP PSD (hazard ratio = 1.24, 95% CI (1.02-1.50) per 1dB).

Conclusions: : "Likely progression" as determined by SAP GPA is not always confirmed on subsequent visual field testing. However, patients with a worse baseline SAP PSD were more likely to have confirmed "likely progression".

Clinical Trial: : http://www.clinicaltrials.gov NCT00221897

Keywords: visual fields • perimetry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×